Nasdaq

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the ...
Medscape

Universal Tests for CMV in Newborns Find More Infections

Congenital CMV is the most common nongenetic cause of hearing loss in children and a leading cause of other neurologic ...
Nasdaq

Fortress Biotech and Helocyte Launch Phase 2 Trial for CMV Vaccine Triplex in Stem Cell Transplant Recipients

Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
THE WEEK

Cytomegalovirus can cause permanent birth defects

Cytomegalovirus (CMV) recently caused a 2-month-old girl in Pennsylvania to suffer severe hearing loss after it was passed to her in the womb. While the virus can exist in a person for life without ...